APO Research
Talk to an analyst

APO RESEARCH · REPORT

Complicated Skin and Skin Structure Infections Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Complicated Skin and Skin Structure Infections Drugs Market Analysis and Forecast 2026-2032

4 July 2026218 pages

Choose your research edition.

Industry ResearchComplicated Skin and Skin Structure Infections Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Complicated Skin and Skin Structure Infections Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Complicated Skin and Skin Structure Infections Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Complicated Skin and Skin Structure Infections Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Complicated Skin and Skin Structure Infections Drugs Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Complicated Skin and Skin Structure Infections Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

Complicated Skin and Skin Structure Infections Drugs's global sales reached XX (t) with a value of US$ XX Million, marking an change of XX% compared to the previous year. This performance has positioned Abbott as the global sales leader, a title it has maintained for several consecutive years. Notably, Abbott's performance in primary markets is also remarkable. In the Chinese market, sales were XX (t), a change of XX% from the previous year. In Europe, sales were XX (t), showing a year-on-year of XX%. In the US, sales were XX (t), a year-on-year change of XX%.

The major global manufacturers in the Complicated Skin and Skin Structure Infections Drugs market include Abbott, Cipla Inc, Dr Reddy's Laboratories Ltd, Endo International Inc, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, Lupin, Melinta Therapeutics, Inc and MerLion Pharmaceuticals GmbH, etc. In 2025, the top three vendors accounted for approximately % of the revenue.

Read the full market overview

In terms of production side, this report researches the Complicated Skin and Skin Structure Infections Drugs production, growth rate, market share by manufacturers and by region (region level and country level), from 2021 to 2026, and forecast to 2032.

In terms of consumption side, this report focuses on the sales of Complicated Skin and Skin Structure Infections Drugs by region (region level and country level), by Company, by Type and by Application. from 2021 to 2026 and forecast to 2032.

This report presents an overview of global market for Complicated Skin and Skin Structure Infections Drugs, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Complicated Skin and Skin Structure Infections Drugs, also provides the consumption of main regions and countries. Of the upcoming market potential for Complicated Skin and Skin Structure Infections Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Complicated Skin and Skin Structure Infections Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Complicated Skin and Skin Structure Infections Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Complicated Skin and Skin Structure Infections Drugs sales, projected growth trends, production technology, application and end-user industry.

Complicated Skin and Skin Structure Infections Drugs Segment by Company

Abbott

Cipla Inc

Dr Reddy's Laboratories Ltd

Endo International Inc

F. Hoffmann-La Roche Ltd

Glenmark Pharmaceuticals Ltd

Lupin

Melinta Therapeutics, Inc

MerLion Pharmaceuticals GmbH

Novartis AG

Paratek Pharmaceuticals, Inc

Pfizer Inc

Teva Pharmaceutical Industries Ltd

Zydus Group

Complicated Skin and Skin Structure Infections Drugs Segment by Type

Vancomycin

Ceftaroline

Tedizolid

Tedizolid

Linezolid

Darbavansing

Olivanstar

Complicated Skin and Skin Structure Infections Drugs Segment by Application

Specialist Clinic

Hospital

Home Care

Other

Complicated Skin and Skin Structure Infections Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Complicated Skin and Skin Structure Infections Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Complicated Skin and Skin Structure Infections Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Complicated Skin and Skin Structure Infections Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Complicated Skin and Skin Structure Infections Drugs production/output of global and key producers (regions/countries). It provides a quantitative analysis of the production, and development potential of each producer in the next six years.

Chapter 4: Sales (consumption), revenue of Complicated Skin and Skin Structure Infections Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 5: Detailed analysis of Complicated Skin and Skin Structure Infections Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Complicated Skin and Skin Structure Infections Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 9: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 10: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 11: China by type, by application, sales, and revenue for each segment.

Chapter 12: Asia (Excluding China) by type, by application and by region, sales, and revenue for each segment.

Chapter 13: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 14: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 15: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Complicated Skin and Skin Structure Infections Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vancomycin Major Manufacturers Table 3. Ceftaroline Major Manufacturers Table 4. Tedizolid Major Manufacturers Table 5. Tedizolid Major Manufacturers Table 6. Linezolid Major Manufacturers Table 7. Darbavansing Major Manufacturers Table 8. Olivanstar Major Manufacturers Table 9. Global Complicated Skin and Skin Structure Infections Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Specialist Clinic Major Manufacturers Table 11. Hospital Major Manufacturers Table 12. Home Care Major Manufacturers Table 13. Other Major Manufacturers Table 14. Complicated Skin and Skin Structure Infections Drugs Industry Trends Table 15. Complicated Skin and Skin Structure Infections Drugs Industry Drivers Table 16. Complicated Skin and Skin Structure Infections Drugs Industry Opportunities and Challenges Table 17. Complicated Skin and Skin Structure Infections Drugs Industry Restraints Table 18. Global Complicated Skin and Skin Structure Infections Drugs Production Growth Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (t) Table 19. Global Complicated Skin and Skin Structure Infections Drugs Production by Region (2021-2026) & (t) Table 20. Global Complicated Skin and Skin Structure Infections Drugs Production by Region (2027-2032) & (t) Table 21. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Region (2021-2026) Table 22. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Region (2027-2032) Table 23. Global Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Complicated Skin and Skin Structure Infections Drugs Revenue by Region (2021-2026) & (US$ Million) Table 25. Global Complicated Skin and Skin Structure Infections Drugs Revenue by Region (2027-2032) & (US$ Million) Table 26. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Region (2021-2026) Table 27. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Region (2027-2032) Table 28. Global Complicated Skin and Skin Structure Infections Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (t) Table 29. Global Complicated Skin and Skin Structure Infections Drugs Sales by Region (2021-2026) & (t) Table 30. Global Complicated Skin and Skin Structure Infections Drugs Sales by Region (2027-2032) & (t) Table 31. Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Region (2021-2026) Table 32. Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Region (2027-2032) Table 33. Global Complicated Skin and Skin Structure Infections Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 34. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Manufacturers (2021-2026) Table 35. Global Complicated Skin and Skin Structure Infections Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 36. Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Manufacturers (2021-2026) Table 37. Global Complicated Skin and Skin Structure Infections Drugs Sales Price (USD/t) of Manufacturers (2021-2026) Table 38. Global Complicated Skin and Skin Structure Infections Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 39. Global Complicated Skin and Skin Structure Infections Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 40. Global Complicated Skin and Skin Structure Infections Drugs Manufacturers, Product Type & Application Table 41. Global Complicated Skin and Skin Structure Infections Drugs Manufacturers Commercialization Time Table 42. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 43. Global Complicated Skin and Skin Structure Infections Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 44. Global Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 45. Global Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 46. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Type (2021-2026) Table 47. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Type (2027-2032) Table 48. Global Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2026) & (t) Table 49. Global Complicated Skin and Skin Structure Infections Drugs Sales by Type (2027-2032) & (t) Table 50. Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Type (2021-2026) Table 51. Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Type (2027-2032) Table 52. Global Complicated Skin and Skin Structure Infections Drugs Price by Type (2021-2026) & (USD/t) Table 53. Global Complicated Skin and Skin Structure Infections Drugs Price by Type (2027-2032) & (USD/t) Table 54. Global Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 55. Global Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 56. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Application (2021-2026) Table 57. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Application (2027-2032) Table 58. Global Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2026) & (t) Table 59. Global Complicated Skin and Skin Structure Infections Drugs Sales by Application (2027-2032) & (t) Table 60. Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Application (2021-2026) Table 61. Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Application (2027-2032) Table 62. Global Complicated Skin and Skin Structure Infections Drugs Price by Application (2021-2026) & (USD/t) Table 63. Global Complicated Skin and Skin Structure Infections Drugs Price by Application (2027-2032) & (USD/t) Table 64. Abbott Company Information Table 65. Abbott Business Overview Table 66. Abbott Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 67. Abbott Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 68. Abbott Recent Development Table 69. Cipla Inc Company Information Table 70. Cipla Inc Business Overview Table 71. Cipla Inc Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 72. Cipla Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 73. Cipla Inc Recent Development Table 74. Dr Reddy's Laboratories Ltd Company Information Table 75. Dr Reddy's Laboratories Ltd Business Overview Table 76. Dr Reddy's Laboratories Ltd Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 77. Dr Reddy's Laboratories Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 78. Dr Reddy's Laboratories Ltd Recent Development Table 79. Endo International Inc Company Information Table 80. Endo International Inc Business Overview Table 81. Endo International Inc Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 82. Endo International Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 83. Endo International Inc Recent Development Table 84. F. Hoffmann-La Roche Ltd Company Information Table 85. F. Hoffmann-La Roche Ltd Business Overview Table 86. F. Hoffmann-La Roche Ltd Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 87. F. Hoffmann-La Roche Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 88. F. Hoffmann-La Roche Ltd Recent Development Table 89. Glenmark Pharmaceuticals Ltd Company Information Table 90. Glenmark Pharmaceuticals Ltd Business Overview Table 91. Glenmark Pharmaceuticals Ltd Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 92. Glenmark Pharmaceuticals Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 93. Glenmark Pharmaceuticals Ltd Recent Development Table 94. Lupin Company Information Table 95. Lupin Business Overview Table 96. Lupin Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 97. Lupin Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 98. Lupin Recent Development Table 99. Melinta Therapeutics, Inc Company Information Table 100. Melinta Therapeutics, Inc Business Overview Table 101. Melinta Therapeutics, Inc Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 102. Melinta Therapeutics, Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 103. Melinta Therapeutics, Inc Recent Development Table 104. MerLion Pharmaceuticals GmbH Company Information Table 105. MerLion Pharmaceuticals GmbH Business Overview Table 106. MerLion Pharmaceuticals GmbH Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 107. MerLion Pharmaceuticals GmbH Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 108. MerLion Pharmaceuticals GmbH Recent Development Table 109. Novartis AG Company Information Table 110. Novartis AG Business Overview Table 111. Novartis AG Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 112. Novartis AG Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 113. Novartis AG Recent Development Table 114. Paratek Pharmaceuticals, Inc Company Information Table 115. Paratek Pharmaceuticals, Inc Business Overview Table 116. Paratek Pharmaceuticals, Inc Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 117. Paratek Pharmaceuticals, Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 118. Paratek Pharmaceuticals, Inc Recent Development Table 119. Pfizer Inc Company Information Table 120. Pfizer Inc Business Overview Table 121. Pfizer Inc Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 122. Pfizer Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 123. Pfizer Inc Recent Development Table 124. Teva Pharmaceutical Industries Ltd Company Information Table 125. Teva Pharmaceutical Industries Ltd Business Overview Table 126. Teva Pharmaceutical Industries Ltd Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 127. Teva Pharmaceutical Industries Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 128. Teva Pharmaceutical Industries Ltd Recent Development Table 129. Zydus Group Company Information Table 130. Zydus Group Business Overview Table 131. Zydus Group Complicated Skin and Skin Structure Infections Drugs Sales (t), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 132. Zydus Group Complicated Skin and Skin Structure Infections Drugs Product Portfolio Table 133. Zydus Group Recent Development Table 134. North America Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 135. North America Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 136. North America Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2026) & (t) Table 137. North America Complicated Skin and Skin Structure Infections Drugs Sales by Type (2027-2032) & (t) Table 138. North America Complicated Skin and Skin Structure Infections Drugs Sales Price by Type (2021-2026) & (USD/t) Table 139. North America Complicated Skin and Skin Structure Infections Drugs Sales Price by Type (2027-2032) & (USD/t) Table 140. North America Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 141. North America Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 142. North America Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2026) & (t) Table 143. North America Complicated Skin and Skin Structure Infections Drugs Sales by Application (2027-2032) & (t) Table 144. North America Complicated Skin and Skin Structure Infections Drugs Sales Price by Application (2021-2026) & (USD/t) Table 145. North America Complicated Skin and Skin Structure Infections Drugs Sales Price by Application (2027-2032) & (USD/t) Table 146. North America Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. North America Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 148. North America Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 149. North America Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021 VS 2025 VS 2032) & (t) Table 150. North America Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021-2026) & (t) Table 151. North America Complicated Skin and Skin Structure Infections Drugs Sales by Country (2027-2032) & (t) Table 152. North America Complicated Skin and Skin Structure Infections Drugs Sales Price by Country (2021-2026) & (USD/t) Table 153. North America Complicated Skin and Skin Structure Infections Drugs Sales Price by Country (2027-2032) & (USD/t) Table 154. United States Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 155. Canada Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 156. Mexico Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 157. Europe Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 158. Europe Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 159. Europe Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2026) & (t) Table 160. Europe Complicated Skin and Skin Structure Infections Drugs Sales by Type (2027-2032) & (t) Table 161. Europe Complicated Skin and Skin Structure Infections Drugs Sales Price by Type (2021-2026) & (USD/t) Table 162. Europe Complicated Skin and Skin Structure Infections Drugs Sales Price by Type (2027-2032) & (USD/t) Table 163. Europe Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 164. Europe Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 165. Europe Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2026) & (t) Table 166. Europe Complicated Skin and Skin Structure Infections Drugs Sales by Application (2027-2032) & (t) Table 167. Europe Complicated Skin and Skin Structure Infections Drugs Sales Price by Application (2021-2026) & (USD/t) Table 168. Europe Complicated Skin and Skin Structure Infections Drugs Sales Price by Application (2027-2032) & (USD/t) Table 169. Europe Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. Europe Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 171. Europe Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 172. Europe Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021 VS 2025 VS 2032) & (t) Table 173. Europe Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021-2026) & (t) Table 174. Europe Complicated Skin and Skin Structure Infections Drugs Sales by Country (2027-2032) & (t) Table 175. Europe Complicated Skin and Skin Structure Infections Drugs Sales Price by Country (2021-2026) & (USD/t) Table 176. Europe Complicated Skin and Skin Structure Infections Drugs Sales Price by Country (2027-2032) & (USD/t) Table 177. Germany Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 178. France Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 179. U.K. Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 180. Italy Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 181. Russia Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 182. Spain Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 183. Netherlands Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 184. Switzerland Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 185. Sweden Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 186. Poland Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 187. China Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 188. China Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 189. China Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2026) & (t) Table 190. China Complicated Skin and Skin Structure Infections Drugs Sales by Type (2027-2032) & (t) Table 191. China Complicated Skin and Skin Structure Infections Drugs Sales Price by Type (2021-2026) & (USD/t) Table 192. China Complicated Skin and Skin Structure Infections Drugs Sales Price by Type (2027-2032) & (USD/t) Table 193. China Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 194. China Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 195. China Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2026) & (t) Table 196. China Complicated Skin and Skin Structure Infections Drugs Sales by Application (2027-2032) & (t) Table 197. China Complicated Skin and Skin Structure Infections Drugs Sales Price by Application (2021-2026) & (USD/t) Table 198. China Complicated Skin and Skin Structure Infections Drugs Sales Price by Application (2027-2032) & (USD/t) Table 199. Asia Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 200. Asia Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 201. Asia Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2026) & (t) Table 202. Asia Complicated Skin and Skin Structure Infections Drugs Sales by Type (2027-2032) & (t) Table 203. Asia Complicated Skin and Skin Structure Infections Drugs Sales Price by Type (2021-2026) & (USD/t) Table 204. Asia Complicated Skin and Skin Structure Infections Drugs Sales Price by Type (2027-2032) & (USD/t) Table 205. Asia Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 206. Asia Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 207. Asia Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2026) & (t) Table 208. Asia Complicated Skin and Skin Structure Infections Drugs Sales by Application (2027-2032) & (t) Table 209. Asia Complicated Skin and Skin Structure Infections Drugs Sales Price by Application (2021-2026) & (USD/t) Table 210. Asia Complicated Skin and Skin Structure Infections Drugs Sales Price by Application (2027-2032) & (USD/t) Table 211. Asia Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 212. Asia Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 213. Asia Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 214. Asia Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021 VS 2025 VS 2032) & (t) Table 215. Asia Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021-2026) & (t) Table 216. Asia Complicated Skin and Skin Structure Infections Drugs Sales by Country (2027-2032) & (t) Table 217. Asia Complicated Skin and Skin Structure Infections Drugs Sales Price by Country (2021-2026) & (USD/t) Table 218. Asia Complicated Skin and Skin Structure Infections Drugs Sales Price by Country (2027-2032) & (USD/t) Table 219. Japan Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 220. South Korea Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 221. India Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 222. Australia Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 223. Taiwan Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 224. Southeast Asia Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 225. SAMEA Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2026) & (US$ Million) Table 226. SAMEA Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2027-2032) & (US$ Million) Table 227. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2026) & (t) Table 228. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales by Type (2027-2032) & (t) Table 229. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales Price by Type (2021-2026) & (USD/t) Table 230. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales Price by Type (2027-2032) & (USD/t) Table 231. SAMEA Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2026) & (US$ Million) Table 232. SAMEA Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2027-2032) & (US$ Million) Table 233. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2026) & (t) Table 234. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales by Application (2027-2032) & (t) Table 235. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales Price by Application (2021-2026) & (USD/t) Table 236. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales Price by Application (2027-2032) & (USD/t) Table 237. SAMEA Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 238. SAMEA Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 239. SAMEA Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 240. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021 VS 2025 VS 2032) & (t) Table 241. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021-2026) & (t) Table 242. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales by Country (2027-2032) & (t) Table 243. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales Price by Country (2021-2026) & (USD/t) Table 244. SAMEA Complicated Skin and Skin Structure Infections Drugs Sales Price by Country (2027-2032) & (USD/t) Table 245. Brazil Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 246. Argentina Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 247. Chile Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 248. Colombia Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 249. Peru Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 250. Saudi Arabia Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 251. Israel Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 252. UAE Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 253. Turkey Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 254. Iran Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 255. Egypt Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Table 256. Key Raw Materials Table 257. Raw Materials Key Suppliers Table 258. Complicated Skin and Skin Structure Infections Drugs Distributors List Table 259. Complicated Skin and Skin Structure Infections Drugs Customers List Table 260. Research Programs/Design for This Report Table 261. Authors List of This Report Table 262. Secondary Sources Table 263. Primary Sources List of Figures Figure 1. Complicated Skin and Skin Structure Infections Drugs Product Image Figure 2. Global Complicated Skin and Skin Structure Infections Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Complicated Skin and Skin Structure Infections Drugs Market Size Share 2021 VS 2025 VS 2032 Figure . Vancomycin Image Figure 1. Ceftaroline Image Figure 2. Tedizolid Image Figure 3. Tedizolid Image Figure 4. Linezolid Image Figure 5. Darbavansing Image Figure 6. Olivanstar Image Figure 7. Global Complicated Skin and Skin Structure Infections Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Complicated Skin and Skin Structure Infections Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Specialist Clinic Image Figure 10. Hospital Image Figure 11. Home Care Image Figure 12. Other Image Figure 13. Global Complicated Skin and Skin Structure Infections Drugs Capacity, Capacity Utilization (2021-2032) & (t) Figure 14. Global Complicated Skin and Skin Structure Infections Drugs Production by Region: 2021 VS 2025 VS 2032 (t) Figure 15. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Region: 2025 Versus 2032 Figure 16. Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Region (2021-2032) Figure 17. North America Complicated Skin and Skin Structure Infections Drugs Production Growth Rate (2021-2032) & (t) Figure 18. Europe Complicated Skin and Skin Structure Infections Drugs Production Growth Rate (2021-2032) & (t) Figure 19. China Complicated Skin and Skin Structure Infections Drugs Production Growth Rate (2021-2032) & (t) Figure 20. Japan Complicated Skin and Skin Structure Infections Drugs Production Growth Rate (2021-2032) & (t) Figure 21. Global Complicated Skin and Skin Structure Infections Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 22. Global Complicated Skin and Skin Structure Infections Drugs Revenue (2021-2032) & (US$ Million) Figure 23. Global Complicated Skin and Skin Structure Infections Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 25. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Region (2021-2032) Figure 26. Global Complicated Skin and Skin Structure Infections Drugs Sales (2021-2032) & (t) Figure 27. Global Complicated Skin and Skin Structure Infections Drugs Sales by Region: 2021 VS 2025 VS 2032 (t) Figure 28. Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Region (2021-2032) Figure 29. North America Complicated Skin and Skin Structure Infections Drugs Sales YoY (2021-2032) & (t) Figure 30. Europe Complicated Skin and Skin Structure Infections Drugs Sales YoY (2021-2032) & (t) Figure 31. China Complicated Skin and Skin Structure Infections Drugs Sales YoY (2021-2032) & (t) Figure 32. Asia (Excluding China) Complicated Skin and Skin Structure Infections Drugs Sales YoY (2021-2032) & (t) Figure 33. South America, Middle East and Africa Complicated Skin and Skin Structure Infections Drugs Sales YoY (2021-2032) & (t) Figure 34. Global Complicated Skin and Skin Structure Infections Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 35. Global Complicated Skin and Skin Structure Infections Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 36. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 37. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Type (2021-2032) Figure 38. Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Type (2021-2032) Figure 39. Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Application (2021-2032) Figure 40. Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Application (2021-2032) Figure 41. North America Complicated Skin and Skin Structure Infections Drugs Revenue Share by Type (2021-2032) Figure 42. North America Complicated Skin and Skin Structure Infections Drugs Sales Share by Type (2021-2032) Figure 43. North America Complicated Skin and Skin Structure Infections Drugs Revenue Share by Application (2021-2032) Figure 44. North America Complicated Skin and Skin Structure Infections Drugs Sales Share by Application (2021-2032) Figure 45. North America Complicated Skin and Skin Structure Infections Drugs Revenue Share by Country (2021-2032) Figure 46. North America Complicated Skin and Skin Structure Infections Drugs Sales Share by Country (2021-2032)

Scope & coverage.

Types
  • Vancomycin
  • Ceftaroline
  • Tedizolid
  • Tedizolid
  • Linezolid
  • Darbavansing
  • Olivanstar
Applications
  • Specialist Clinic
  • Hospital
  • Home Care
  • Other
Companies covered
  • Abbott
  • Cipla Inc
  • Dr Reddy's Laboratories Ltd
  • Endo International Inc
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Ltd
  • Lupin
  • Melinta Therapeutics, Inc
  • MerLion Pharmaceuticals GmbH
  • Novartis AG
  • Paratek Pharmaceuticals, Inc
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Zydus Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Complicated Skin and Skin Structure Infections Drugs Market by Type
  3. 1.2.1 Global Complicated Skin and Skin Structure Infections Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vancomycin
  5. 1.2.3 Ceftaroline
  6. 1.2.4 Tedizolid
  7. 1.2.5 Tedizolid
  8. 1.2.6 Linezolid
  9. 1.2.7 Darbavansing
  10. 1.2.8 Olivanstar
  11. 1.3 Complicated Skin and Skin Structure Infections Drugs Market by Application
  12. 1.3.1 Global Complicated Skin and Skin Structure Infections Drugs Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Specialist Clinic
  14. 1.3.3 Hospital
  15. 1.3.4 Home Care
  16. 1.3.5 Other
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Complicated Skin and Skin Structure Infections Drugs Market Dynamics
  1. 2.1 Complicated Skin and Skin Structure Infections Drugs Industry Trends
  2. 2.2 Complicated Skin and Skin Structure Infections Drugs Industry Drivers
  3. 2.3 Complicated Skin and Skin Structure Infections Drugs Industry Opportunities and Challenges
  4. 2.4 Complicated Skin and Skin Structure Infections Drugs Industry Restraints
3 Global Complicated Skin and Skin Structure Infections Drugs Production Overview
  1. 3.1 Global Complicated Skin and Skin Structure Infections Drugs Production Capacity (2021-2032)
  2. 3.2 Global Complicated Skin and Skin Structure Infections Drugs Production by Region: 2021 VS 2025 VS 2032
  3. 3.3 Global Complicated Skin and Skin Structure Infections Drugs Production by Region
  4. 3.3.1 Global Complicated Skin and Skin Structure Infections Drugs Production by Region (2021-2026)
  5. 3.3.2 Global Complicated Skin and Skin Structure Infections Drugs Production by Region (2027-2032)
  6. 3.3.3 Global Complicated Skin and Skin Structure Infections Drugs Production Market Share by Region (2021-2032)
  7. 3.4 North America
  8. 3.5 Europe
  9. 3.6 China
  10. 3.7 Japan
4 Global Market Growth Prospects
  1. 4.1 Global Complicated Skin and Skin Structure Infections Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 4.2 Global Complicated Skin and Skin Structure Infections Drugs Revenue by Region
  3. 4.2.1 Global Complicated Skin and Skin Structure Infections Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 4.2.2 Global Complicated Skin and Skin Structure Infections Drugs Revenue by Region (2021-2026)
  5. 4.2.3 Global Complicated Skin and Skin Structure Infections Drugs Revenue by Region (2027-2032)
  6. 4.2.4 Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Region (2021-2032)
  7. 4.3 Global Complicated Skin and Skin Structure Infections Drugs Sales Estimates and Forecasts 2021-2032
  8. 4.4 Global Complicated Skin and Skin Structure Infections Drugs Sales by Region
  9. 4.4.1 Global Complicated Skin and Skin Structure Infections Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 4.4.2 Global Complicated Skin and Skin Structure Infections Drugs Sales by Region (2021-2026)
  11. 4.4.3 Global Complicated Skin and Skin Structure Infections Drugs Sales by Region (2027-2032)
  12. 4.4.4 Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Region (2021-2032)
  13. 4.5 North America
  14. 4.6 Europe
  15. 4.7 China
  16. 4.8 Asia (Excluding China)
  17. 4.9 South America, Middle East and Africa
5 Market Competitive Landscape by Manufacturers
  1. 5.1 Global Complicated Skin and Skin Structure Infections Drugs Revenue by Manufacturers
  2. 5.1.1 Global Complicated Skin and Skin Structure Infections Drugs Revenue by Manufacturers (2021-2026)
  3. 5.1.2 Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 5.1.3 Global Complicated Skin and Skin Structure Infections Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 5.2 Global Complicated Skin and Skin Structure Infections Drugs Sales by Manufacturers
  6. 5.2.1 Global Complicated Skin and Skin Structure Infections Drugs Sales by Manufacturers (2021-2026)
  7. 5.2.2 Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 5.2.3 Global Complicated Skin and Skin Structure Infections Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 5.3 Global Complicated Skin and Skin Structure Infections Drugs Sales Price by Manufacturers (2021-2026)
  10. 5.4 Global Complicated Skin and Skin Structure Infections Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 5.5 Global Complicated Skin and Skin Structure Infections Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 5.6 Global Complicated Skin and Skin Structure Infections Drugs Manufacturers, Product Type & Application
  13. 5.7 Global Complicated Skin and Skin Structure Infections Drugs Manufacturers Commercialization Time
  14. 5.8 Market Competitive Analysis
  15. 5.8.1 Global Complicated Skin and Skin Structure Infections Drugs Market CR5 and HHI
  16. 5.8.2 2025 Complicated Skin and Skin Structure Infections Drugs Tier 1, Tier 2, and Tier 3
6 Complicated Skin and Skin Structure Infections Drugs Market by Type
  1. 6.1 Global Complicated Skin and Skin Structure Infections Drugs Revenue by Type
  2. 6.1.1 Global Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2032) & (US$ Million)
  3. 6.1.2 Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Type (2021-2032)
  4. 6.2 Global Complicated Skin and Skin Structure Infections Drugs Sales by Type
  5. 6.2.1 Global Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2032) & (t)
  6. 6.2.2 Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Type (2021-2032)
  7. 6.3 Global Complicated Skin and Skin Structure Infections Drugs Price by Type
7 Complicated Skin and Skin Structure Infections Drugs Market by Application
  1. 7.1 Global Complicated Skin and Skin Structure Infections Drugs Revenue by Application
  2. 7.1.1 Global Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2032) & (US$ Million)
  3. 7.1.2 Global Complicated Skin and Skin Structure Infections Drugs Revenue Market Share by Application (2021-2032)
  4. 7.2 Global Complicated Skin and Skin Structure Infections Drugs Sales by Application
  5. 7.2.1 Global Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2032) & (t)
  6. 7.2.2 Global Complicated Skin and Skin Structure Infections Drugs Sales Market Share by Application (2021-2032)
  7. 7.3 Global Complicated Skin and Skin Structure Infections Drugs Price by Application
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Cipla Inc
  8. 8.2.1 Cipla Inc Company Information
  9. 8.2.2 Cipla Inc Business Overview
  10. 8.2.3 Cipla Inc Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 8.2.4 Cipla Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  12. 8.2.5 Cipla Inc Recent Developments
  13. 8.3 Dr Reddy's Laboratories Ltd
  14. 8.3.1 Dr Reddy's Laboratories Ltd Company Information
  15. 8.3.2 Dr Reddy's Laboratories Ltd Business Overview
  16. 8.3.3 Dr Reddy's Laboratories Ltd Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 8.3.4 Dr Reddy's Laboratories Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  18. 8.3.5 Dr Reddy's Laboratories Ltd Recent Developments
  19. 8.4 Endo International Inc
  20. 8.4.1 Endo International Inc Company Information
  21. 8.4.2 Endo International Inc Business Overview
  22. 8.4.3 Endo International Inc Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 8.4.4 Endo International Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  24. 8.4.5 Endo International Inc Recent Developments
  25. 8.5 F. Hoffmann-La Roche Ltd
  26. 8.5.1 F. Hoffmann-La Roche Ltd Company Information
  27. 8.5.2 F. Hoffmann-La Roche Ltd Business Overview
  28. 8.5.3 F. Hoffmann-La Roche Ltd Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 8.5.4 F. Hoffmann-La Roche Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  30. 8.5.5 F. Hoffmann-La Roche Ltd Recent Developments
  31. 8.6 Glenmark Pharmaceuticals Ltd
  32. 8.6.1 Glenmark Pharmaceuticals Ltd Company Information
  33. 8.6.2 Glenmark Pharmaceuticals Ltd Business Overview
  34. 8.6.3 Glenmark Pharmaceuticals Ltd Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 8.6.4 Glenmark Pharmaceuticals Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  36. 8.6.5 Glenmark Pharmaceuticals Ltd Recent Developments
  37. 8.7 Lupin
  38. 8.7.1 Lupin Company Information
  39. 8.7.2 Lupin Business Overview
  40. 8.7.3 Lupin Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 8.7.4 Lupin Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  42. 8.7.5 Lupin Recent Developments
  43. 8.8 Melinta Therapeutics, Inc
  44. 8.8.1 Melinta Therapeutics, Inc Company Information
  45. 8.8.2 Melinta Therapeutics, Inc Business Overview
  46. 8.8.3 Melinta Therapeutics, Inc Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 8.8.4 Melinta Therapeutics, Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  48. 8.8.5 Melinta Therapeutics, Inc Recent Developments
  49. 8.9 MerLion Pharmaceuticals GmbH
  50. 8.9.1 MerLion Pharmaceuticals GmbH Company Information
  51. 8.9.2 MerLion Pharmaceuticals GmbH Business Overview
  52. 8.9.3 MerLion Pharmaceuticals GmbH Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 8.9.4 MerLion Pharmaceuticals GmbH Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  54. 8.9.5 MerLion Pharmaceuticals GmbH Recent Developments
  55. 8.10 Novartis AG
  56. 8.10.1 Novartis AG Company Information
  57. 8.10.2 Novartis AG Business Overview
  58. 8.10.3 Novartis AG Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 8.10.4 Novartis AG Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  60. 8.10.5 Novartis AG Recent Developments
  61. 8.11 Paratek Pharmaceuticals, Inc
  62. 8.11.1 Paratek Pharmaceuticals, Inc Company Information
  63. 8.11.2 Paratek Pharmaceuticals, Inc Business Overview
  64. 8.11.3 Paratek Pharmaceuticals, Inc Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 8.11.4 Paratek Pharmaceuticals, Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  66. 8.11.5 Paratek Pharmaceuticals, Inc Recent Developments
  67. 8.12 Pfizer Inc
  68. 8.12.1 Pfizer Inc Company Information
  69. 8.12.2 Pfizer Inc Business Overview
  70. 8.12.3 Pfizer Inc Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Inc Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  72. 8.12.5 Pfizer Inc Recent Developments
  73. 8.13 Teva Pharmaceutical Industries Ltd
  74. 8.13.1 Teva Pharmaceutical Industries Ltd Company Information
  75. 8.13.2 Teva Pharmaceutical Industries Ltd Business Overview
  76. 8.13.3 Teva Pharmaceutical Industries Ltd Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 8.13.4 Teva Pharmaceutical Industries Ltd Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  78. 8.13.5 Teva Pharmaceutical Industries Ltd Recent Developments
  79. 8.14 Zydus Group
  80. 8.14.1 Zydus Group Company Information
  81. 8.14.2 Zydus Group Business Overview
  82. 8.14.3 Zydus Group Complicated Skin and Skin Structure Infections Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 8.14.4 Zydus Group Complicated Skin and Skin Structure Infections Drugs Product Portfolio
  84. 8.14.5 Zydus Group Recent Developments
9 North America
  1. 9.1 North America Complicated Skin and Skin Structure Infections Drugs Market Size by Type
  2. 9.1.1 North America Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2032)
  3. 9.1.2 North America Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2032)
  4. 9.1.3 North America Complicated Skin and Skin Structure Infections Drugs Price by Type (2021-2032)
  5. 9.2 North America Complicated Skin and Skin Structure Infections Drugs Market Size by Application
  6. 9.2.1 North America Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2032)
  7. 9.2.2 North America Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2032)
  8. 9.2.3 North America Complicated Skin and Skin Structure Infections Drugs Price by Application (2021-2032)
  9. 9.3 North America Complicated Skin and Skin Structure Infections Drugs Market Size by Country
  10. 9.3.1 North America Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 North America Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 North America Complicated Skin and Skin Structure Infections Drugs Price by Country (2021-2032)
  13. 9.3.4 United States
  14. 9.3.5 Canada
  15. 9.3.6 Mexico
10 Europe
  1. 10.1 Europe Complicated Skin and Skin Structure Infections Drugs Market Size by Type
  2. 10.1.1 Europe Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2032)
  3. 10.1.2 Europe Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2032)
  4. 10.1.3 Europe Complicated Skin and Skin Structure Infections Drugs Price by Type (2021-2032)
  5. 10.2 Europe Complicated Skin and Skin Structure Infections Drugs Market Size by Application
  6. 10.2.1 Europe Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2032)
  7. 10.2.2 Europe Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2032)
  8. 10.2.3 Europe Complicated Skin and Skin Structure Infections Drugs Price by Application (2021-2032)
  9. 10.3 Europe Complicated Skin and Skin Structure Infections Drugs Market Size by Country
  10. 10.3.1 Europe Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 10.3.2 Europe Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 10.3.3 Europe Complicated Skin and Skin Structure Infections Drugs Price by Country (2021-2032)
  13. 10.3.4 Germany
  14. 10.3.5 France
  15. 10.3.6 U.K.
  16. 10.3.7 Italy
  17. 10.3.8 Russia
  18. 10.3.9 Spain
  19. 10.3.10 Netherlands
  20. 10.3.11 Switzerland
  21. 10.3.12 Sweden
11 China
  1. 11.1 China Complicated Skin and Skin Structure Infections Drugs Market Size by Type
  2. 11.1.1 China Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2032)
  3. 11.1.2 China Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2032)
  4. 11.1.3 China Complicated Skin and Skin Structure Infections Drugs Price by Type (2021-2032)
  5. 11.2 China Complicated Skin and Skin Structure Infections Drugs Market Size by Application
  6. 11.2.1 China Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2032)
  7. 11.2.2 China Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2032)
  8. 11.2.3 China Complicated Skin and Skin Structure Infections Drugs Price by Application (2021-2032)
12 Asia (Excluding China)
  1. 12.1 Asia Complicated Skin and Skin Structure Infections Drugs Market Size by Type
  2. 12.1.1 Asia Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2032)
  3. 12.1.2 Asia Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2032)
  4. 12.1.3 Asia Complicated Skin and Skin Structure Infections Drugs Price by Type (2021-2032)
  5. 12.2 Asia Complicated Skin and Skin Structure Infections Drugs Market Size by Application
  6. 12.2.1 Asia Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2032)
  7. 12.2.2 Asia Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2032)
  8. 12.2.3 Asia Complicated Skin and Skin Structure Infections Drugs Price by Application (2021-2032)
  9. 12.3 Asia Complicated Skin and Skin Structure Infections Drugs Market Size by Country
  10. 12.3.1 Asia Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 Asia Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 Asia Complicated Skin and Skin Structure Infections Drugs Price by Country (2021-2032)
  13. 12.3.4 Japan
  14. 12.3.5 South Korea
  15. 12.3.6 India
  16. 12.3.7 Australia
  17. 12.3.8 Taiwan
  18. 12.3.9 Southeast Asia
13 South America, Middle East and Africa
  1. 13.1 SAMEA Complicated Skin and Skin Structure Infections Drugs Market Size by Type
  2. 13.1.1 SAMEA Complicated Skin and Skin Structure Infections Drugs Revenue by Type (2021-2032)
  3. 13.1.2 SAMEA Complicated Skin and Skin Structure Infections Drugs Sales by Type (2021-2032)
  4. 13.1.3 SAMEA Complicated Skin and Skin Structure Infections Drugs Price by Type (2021-2032)
  5. 13.2 SAMEA Complicated Skin and Skin Structure Infections Drugs Market Size by Application
  6. 13.2.1 SAMEA Complicated Skin and Skin Structure Infections Drugs Revenue by Application (2021-2032)
  7. 13.2.2 SAMEA Complicated Skin and Skin Structure Infections Drugs Sales by Application (2021-2032)
  8. 13.2.3 SAMEA Complicated Skin and Skin Structure Infections Drugs Price by Application (2021-2032)
  9. 13.3 SAMEA Complicated Skin and Skin Structure Infections Drugs Market Size by Country
  10. 13.3.1 SAMEA Complicated Skin and Skin Structure Infections Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 13.3.2 SAMEA Complicated Skin and Skin Structure Infections Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 13.3.3 SAMEA Complicated Skin and Skin Structure Infections Drugs Price by Country (2021-2032)
  13. 13.3.4 Brazil
  14. 13.3.5 Argentina
  15. 13.3.6 Chile
  16. 13.3.7 Colombia
  17. 13.3.8 Peru
  18. 13.3.9 Saudi Arabia
  19. 13.3.10 Israel
  20. 13.3.11 UAE
  21. 13.3.12 Turkey
  22. 13.3.13 Iran
  23. 13.3.14 Egypt
14 Value Chain and Sales Channels Analysis
  1. 14.1 Complicated Skin and Skin Structure Infections Drugs Value Chain Analysis
  2. 14.1.1 Complicated Skin and Skin Structure Infections Drugs Key Raw Materials
  3. 14.1.2 Raw Materials Key Suppliers
  4. 14.1.3 Manufacturing Cost Structure
  5. 14.1.4 Complicated Skin and Skin Structure Infections Drugs Production Mode & Process
  6. 14.2 Complicated Skin and Skin Structure Infections Drugs Sales Channels Analysis
  7. 14.2.1 Direct Comparison with Distribution Share
  8. 14.2.2 Complicated Skin and Skin Structure Infections Drugs Distributors
  9. 14.2.3 Complicated Skin and Skin Structure Infections Drugs Customers
15 Concluding Insights
    16 Appendix
    1. 16.1 Reasons for Doing This Study
    2. 16.2 Research Methodology
    3. 16.3 Research Process
    4. 16.4 Authors List of This Report
    5. 16.5 Data Source
    6. 16.5.1 Secondary Sources
    7. 16.5.2 Primary Sources
    8. 16.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst